Not Yet RecruitingNCT03833206
Safety and dose finding of PDC-1421 for depression during cancer care
About this title
Read the official source — NCT03833206Medication studyAges 21–85United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 21 years to 85 years. Other eligibility criteria apply.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: January 15, 2027
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 12
- Sponsor
- BioLite, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 21 Years to 85 Years
- Official registry ID
- NCT03833206
- Official title
Show the full official title
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioLite, Inc.
Does this study involve medication?
Yes. The study involves medication, including PDC-1421 Capsule.
Who can participate?
This study is for people with depression. Listed age limits: 21 years to 85 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
